行情

NKTR

NKTR

内克塔治疗
NASDAQ

实时行情|Nasdaq Last Sale

21.85
+0.34
+1.58%
盘后: 21.97 +0.12 +0.55% 19:36 08/07 EDT
开盘
22.50
昨收
21.51
最高
22.98
最低
21.74
成交量
126.03万
成交额
--
52周最高
29.99
52周最低
13.63
市值
38.89亿
市盈率(TTM)
-8.3416
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NKTR价格均价为31.14,最高价位80.00,最低价为18.00。

EPS

NKTR 新闻

更多
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Zacks · 1天前
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2天前
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
PR Newswire · 2天前
Earnings Preview: Nektar Therapeutics (NKTR) Q2 Earnings Expected to Decline
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to
PR Newswire · 07/28 22:00
Medicenna Company Update And Upcoming Catalysts
Seeking Alpha - Article · 07/01 16:38
Hedge Funds Arent Impressed By Nektar Therapeutics (NKTR)
Insider Monkey · 06/24 02:46
Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/15 02:25

所属板块

生物技术和医学研究
-0.18%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

NKTR 简况

Nektar Therapeutics是一家生物制药公司,在医疗需求未得到满足的地区发现和开发药物。该公司新研究药物的研发线包括癌症和自身免疫性疾病的治疗。它利用其化学平台来发现和设计新的候选药物。这些候选药物利用其聚合物共轭技术平台旨在开发针对已知作用机理的新分子实体。该公司项目包括免疫肿瘤学(I-O)、免疫学和肿瘤学ONZEALD。它正在开发直接或间接调节关键免疫细胞(如细胞毒性T细胞和自然杀伤(NK)细胞)活性的药物,以增加其数量并改善其识别和攻击癌细胞的功能。
展开

微牛提供Nektar Therapeutics(NASDAQ-NKTR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NKTR股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NKTR股票基本功能。